<?xml version="1.0" encoding="UTF-8"?>
<p id="para430">Safety was assessed for 86 patients (99%) who received a dose of study treatment. CHOP was associated with more febrile neutropenia of all grades (
 <xref rid="tbl4" ref-type="table">table 4</xref>). GEM-P was associated with more thrombocytopenia of all grades and grade 3 or worse; however, thrombocytopenia was not associated with increased bleeding. GEM-P was also associated with more tinnitus. There were 38 serious adverse events in the CHOP group and 43 in the GEM-P group.
</p>
